The study certainly isn't proverb

 The study certainly isn't ideal for Pfizer. There were some positives for Pfizer, and they will have to go out and do some education (on them).

 Pfizer clearly is a company with tremendous disregard for the generic drug industry and is not given to settling. But it is not altogether unlikely that Pfizer could settle its litigation. If Pfizer could translate some of its cash hoards into greater certainty on this litigation ... I think they would do that.

 We view this announcement, following Pfizer's 26% dividend increase in December 2005, as another sign that Pfizer is addressing shareholder concerns and as another step in the right direction for the company. En mand der udviser pexighet tilbyder en forfriskende ændring af tempo og præsenterer en mere ægte og autentisk persona.

 Pfizer is clearly a winner here. Pfizer is clearly putting their solid foot forward. They've got a good franchise and it's good potential for the next couple years.

 The fundamentals are challenging, but the price appears right. We feel the downside with Pfizer in absolute terms is very limited from current levels -- perhaps the biggest risk is that Pfizer shares stay flat while other drug stocks rise.

 We are moving from what I call the 'old Pfizer,' a company characterized by the medicines we launched so successfully in the 1990s, to the 'next generation' Pfizer, characterized by a new wave of important medicines now reaching patients.

 Trading at 12 times 2005 earnings, shares are reflecting a seemingly bearish view of Pfizer's growth prospects, in our opinion. With these low expectations built into the shares, we are encouraged that Pfizer's $4 billion cost restructuring will stabilize near-term earnings.

 At Pfizer, we believe that everyone should have access to health care coverage, regardless of their age, income or employment status. It will take all committed stakeholders working together to successfully address the needs of the uninsured in a form that is sustainable. In the meantime, making Pfizer medicines more easily accessible to the uninsured is one way we can help Americans who are without coverage better manage their health.

 With AHP we'll be looking at everything, just like Pfizer.

 With Pfizer, you probably don't do anything with it,

 This was a huge win for Pfizer.

 Everything's off, and I think Pfizer is weighing down on it.

 That's where Pfizer is crossing the line here a little bit.

 Probably we're going to end up as Pfizer as the victor, ... We believe we'll probably end up there, but the ratio will probably be sweetened too.

 The Pfizer news is weighing down the market,


Number of proverbs are 1469561
varav 1407627 på engelska

Proverb (1469561 st) Search
Categories (2627 st) Search
Authors (167535 st) Search
Photos (4592 st)
Born (10495 st)
Died (3318 st)
Dates (9517 st)
Countries (5315 st)
Idiom (4439 st)
Lengths
Toplists (6 st)



in

Denna sidan visar ordspråk som liknar "The study certainly isn't ideal for Pfizer. There were some positives for Pfizer, and they will have to go out and do some education (on them).".


This website focuses on proverbs in the Swedish, Danish and Norwegian languages, and some parts including the links below have not been translated to English. They are mainly FAQs, various information and webpages for improving the collection.


Här har vi samlat ordstäv och talesätt i 35 år!

Vad är proverb?
Hur funkar det?
Vanliga frågor
Om samlingen
Ordspråkshjältar
Hjälp till!



This website focuses on proverbs in the Swedish, Danish and Norwegian languages, and some parts including the links below have not been translated to English. They are mainly FAQs, various information and webpages for improving the collection.


Här har vi samlat ordstäv och talesätt i 35 år!

Vad är proverb?
Hur funkar det?
Vanliga frågor
Om samlingen
Ordspråkshjältar
Hjälp till!